利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

221 records (took 0.036 seconds)

    ANTI-FUCOSYLCERAMIDE MONOCLONAL ANTIBODY
    81.
    发明专利
    ANTI-FUCOSYLCERAMIDE MONOCLONAL ANTIBODY 失效

    公开(公告)号：JPH02128697A

    公开(公告)日：1990-05-17

    申请号：JP28143388

    申请日：1988-11-09

    Applicant: HOECHST JAPAN

    Inventor： ISHIHARA HIDEMOTO ,  HATTORI HIROSHI ,  ONO KENICHI

    IPC: G01N33/574 ,  A61K39/395 ,  C07K16/30 ,  C12N5/10 ,  C12N5/24 ,  C12N15/02 ,  C12P21/08 ,  C12R1/91 ,  G01N33/577

    Abstract: NEW MATERIAL:A monoclonal antibody capable of specifically recognizing fucosylceramides having the following properties. Ig class: IgM and derivation of the fucosylceramides: ceramide monoglycoside fraction of neutral glucolipid obtained by extraction from human cancer tissue and purification thereof. Capable of reacting with cell lines derived from lung cancer, stomach cancer, colon cancer and noma. Having no reactivity with cells of normal peripheral blood lymphocyte, normal erythrocyte, normal fibroblast, leukemia, cancer of the liver, mammary cancer, neutrablastoma, etc. USE:A diagnostic for human cancer. PREPARATION:A zooblast is immunized with a neutral glucolipid fraction obtained, e.g., by separation from human noma tissue and purification thereof and the resultant immunized zooblast is fused with a myeloma cell to form a hybridoma. The resultant hybridoma is subjected to cloning and a clone line capable of producing a monoclonal antibody specifically recognizing fucosylceramides is selected therefrom. The selected clone is cultured to obtain the objective monoclonal antibody.

    PRODUCTION OF INSTRUMENT FOR MEASURING ANTINUCLEAR ANTIBODY
    82.
    发明专利
    PRODUCTION OF INSTRUMENT FOR MEASURING ANTINUCLEAR ANTIBODY 失效

    公开(公告)号：JPH01316662A

    公开(公告)日：1989-12-21

    申请号：JP7662089

    申请日：1989-03-30

    Applicant: HOECHST JAPAN

    Inventor： JITSUKAWA TOMOSHI

    IPC: G01N33/564

    Abstract: PURPOSE:To easily measure the antinuclear antibody in blood or bodily fluid with high accuracy by bringing the suspension of cell nuclei into contact with a base to adsorb the cell nuclei in the base and separating the base from the suspension, then fixing the cell nuclei to the base. CONSTITUTION:Nuclear fractions are taken by subjecting the ground liquid of cells to a centrifugal sepn. The nuclear fractions are suspended in a hypotonic liquid to prepare the suspension of the nuclear fractions. The nuclear fraction suspension is brought into direct contact with the base, more preferably plastic base of polystyrene, etc., to adsorb the nuclear fractions to the base. The plastic base and the nuclear fraction suspension are then separated and are treated with a 50-90% acetone soln. to fix the nuclear fractions to the plastic base. The measurement of the antinuclear antibody which allows the sufficient measurement with 100-times dilute serum, has good sensitivity and decreases the background by the nonspecific antibody coexisting in the specimen is executable with the cell nuclei-deposited plastic ELISA plate formed by such treatments.

    NOVEL PROTEIN INDUCED FROM HUMAN ALPHA2-PLASMIN INHIBITOR OR ITS ANALOGOUS PROTEIN
    83.
    发明专利
    NOVEL PROTEIN INDUCED FROM HUMAN ALPHA2-PLASMIN INHIBITOR OR ITS ANALOGOUS PROTEIN 失效

    公开(公告)号：JPH01191687A

    公开(公告)日：1989-08-01

    申请号：JP1576288

    申请日：1988-01-28

    Applicant: HOECHST JAPAN

    Inventor： TOBA MARI ,  TONE MASAHIDE ,  KIKUNO REIKO ,  HASHIMOTO TAMOTSU

    IPC: C12N15/09 ,  A61K38/00 ,  A61K38/55 ,  A61P7/02 ,  C07K14/00 ,  C07K14/81 ,  C07K19/00 ,  C12P21/02 ,  C12R1/19

    Abstract: PURPOSE:To obtain a protein having blood coagulation preventing activity and usable for the prevention, treatment or remedy for cardiovascular disorder or cardiovascular diseases, by modifying a part of alpha2-plasmin inhibitor (alpha2-PI) in human plasma. CONSTITUTION:A gene of alpha2-PI is treated with a restriction enzyme to eliminate the region to be depleted and, if necessary, a gene corresponding to the amino acid sequence of the reactive site of AT-III or its surrounding regions is integrated into the depleted site to obtain a modified gene and produce the objective protein by generic engineering technique. The protein has an amino terminal of formula I and a carboxy terminal of formula II and is depleted of a reactive site cut with a plasmid of alpha2-PI (or analogous protein) or its circumferential region or substituted with a reactive site cut with thrombin of a serine protease inhibitor having antithrombin activity and its circumferential region.

    ANTIPEPTIC ULCER AGENT
    86.
    发明专利
    ANTIPEPTIC ULCER AGENT 失效

    公开(公告)号：JPS63225317A

    公开(公告)日：1988-09-20

    申请号：JP23754087

    申请日：1987-09-24

    Applicant: HOECHST JAPAN

    Inventor： SAKURAI MASAO ,  GOTO MASAYOSHI ,  TANAKA SHUNZO

    IPC: C07D473/06 ,  A61K31/52 ,  A61K31/522 ,  A61P1/04

    Abstract: PURPOSE:To obtain an antipeptic ulcer agent, containing propentofylline and a compound analogous thereof an active ingredient and having excellent remedial effects and high safety. CONSTITUTION:An antipeptic ulcer agent obtained by containing a compound expressed by the formula (R1 is 4-oxopentyl or 5-oxohexyl; R2 is methyl or ethyl; R3 is 2-4C alkyl), e.g. 3,7-dihydro-3-methl-1-(5-oxohexyl)-7-propyl-1H- purine-2,6--dione (common name; propentofylline), as an active ingredient. The above-mentioned compound can be orally, intravenously and intrarectally administered and subcutaneously and intramuscularly injected and the clinical dose thereof is 300-900mg/60kg body weight, preferably 150-600mg/60kg body weight.

    Preparation of color matrix
    88.
    发明专利
    Preparation of color matrix 失效
    彩色矩阵的准备

    公开(公告)号：JPS6132847A

    公开(公告)日：1986-02-15

    申请号：JP15619684

    申请日：1984-07-25

    Applicant: Hoechst Japan Kk

    Inventor： ITO KUNIO

    IPC: H01J9/233 ,  B32B33/00 ,  G02B5/20 ,  G02F1/133 ,  G02F1/1335 ,  G03C5/00 ,  G03C11/00 ,  G03F7/26 ,  G03F7/40 ,  G09F9/35

    CPC classification number: G03F1/56

    Abstract: PURPOSE:To prevent the protein layer dyed in the preceding step from being again dyed and to obtain a sharp multicolor pattern by using the laminate of a water-soluble protein layer and a photoresist layer, dyeing the disclosed protein layer by the photoetching method, treating it with formaldehyde, and repeating this operation in accordance with the number of the colors of the color pattern. CONSTITUTION:The laminate obtained by forming the protein layer and the photoresist layer on a base made of glass, quartz, or the like is exposed in a desired pattern by the photoetching method, and developed to patternwise disclose the lower protein layer which is dyed and treated with formaldehyde, e.g., by dissolving paraformaldehyde or the like in a solvent, and coating or immersing the layer with said soln. or into it generally at 30-100 deg.C, thus permitting the first color pattern to be formed on the surface of the laminate, and then, the second color and the third color patterns different in color from each other to be formed likewise in succession.

    Abstract translation: 目的：为了防止前一步骤中染色的蛋白质层再次染色，并通过使用水溶性蛋白质层和光致抗蚀剂层的层压体获得尖锐的多色图案，通过光刻法对所公开的蛋白质层进行染色， 它与甲醛，并根据颜色图案的颜色的数量重复该操作。 构成：通过在玻璃，石英等制成的基底上形成蛋白质层和光致抗蚀剂层而获得的层压体通过光刻法以期望的图案曝光，并显影以图案化地公开被染色的下层蛋白质层 用甲醛处理，例如通过将多聚甲醛等溶解在溶剂中，以及用所述溶胶涂覆或浸渍该层。 或者通常在30-100℃下，从而允许在层叠体的表面上形成第一颜色图案，然后，将颜色彼此不同的第二颜色和第三颜色图案形成为类似于 演替。

    LIQUID CRYSTAL DISPLAY DEVICE USING FERROELECTRIC LIQUID CRYSTAL
    89.
    发明专利
    LIQUID CRYSTAL DISPLAY DEVICE USING FERROELECTRIC LIQUID CRYSTAL 失效

    公开(公告)号：JPH1172767A

    公开(公告)日：1999-03-16

    申请号：JP14754798

    申请日：1998-05-28

    Applicant: HOECHST JAPAN

    Inventor： HARADA TAKAMASA ,  TAKECHI AYAKO ,  NONAKA TOSHIAKI ,  RI KEI

    IPC: G02F1/137 ,  G02F1/133 ,  G02F1/141 ,  G09F9/35

    Abstract: PROBLEM TO BE SOLVED: To provide a display with multigradation compared with a conventional device by controlling a ferroelectric liquid crystal material to have high- voltage induced oriented states U3 and U4. SOLUTION: A ferroelectric liquid crystal 18 in C2U orientation state is injected between an orienting film 14 and pixel electrodes 17, while the distance between the orienting film 14 and the pixel electrodes 17 is maintained const. by a spacer 19 sprayed or formed as walls at proper positions on the substrate. The ferroelectric liquid crystal material 18 with C2U orientation shows U2 orientation state when positive voltage is applied and shows U1 orientation when negative voltage is applied. Further, when larger positive voltage is applied, the liquid crystal shows U4 orientation state, and when larger negative voltage is applied, it shows U3 orientation state. Therefore, the liquid crystal material 18 shows any desired orientation state between U1 and U3 states and any desired orientation state from U1, through U2 to U4, according to positive or negative voltages applied. Therefore, the quantity of transmitted light can be continuously changed and a display with multigradation can be obtd.

    PHASE SHIFTER AND ITS PRODUCTION
    90.
    发明专利
    PHASE SHIFTER AND ITS PRODUCTION 失效

    公开(公告)号：JPH112721A

    公开(公告)日：1999-01-06

    申请号：JP15465797

    申请日：1997-06-12

    Applicant: HOECHST JAPAN

    Inventor： AIZAWA MASAMI ,  NOZAWA FUMIE

    IPC: G02B5/30 ,  C08L101/02 ,  G02F1/1335

    Abstract: PROBLEM TO BE SOLVED: To obtain a phase shifter having two regions; a region positive in retardation and a region negative in retardation in one phase shifter by irradiating part of the regions of an org. high-polymer film subjected to a uniaxial treatment with UV rays or electronic rays. SOLUTION: The regions of the org. high-polymer film subjected to the uniaxial treatment are irradiated with the UV rays or electron rays, by which the region positive in the retardation and the region negative in the retardation are formed on the org. high-polymer film. In such a case, the high-polymer film of which the retardation changes from positive to negative is used when irradiated with the UV rays or electron rays after the film is subjected to an orientation treatment in the direction where the retardation is position. For example, a photosensitive high polymer, such as polyvinyl cinnamate, having an unsatd. bond in a molecular chain is usable as the material for producing such high-polymer film. A dimerization reaction or isomerization reaction occurs in such high polymer by irradiation with the UV rays, by which the direction of the retardation thereof is changed from negative top positive.

Patent Agency Ranking